Oncology Drug Approval News Flash: Sunvozertinib (Zegfrovy) Approved for EGFR Exon20 Insertion-Positive NSCLC

TOC

[FDA Accelerated Approval] New Oral TKI for Advanced NSCLC with EGFR Exon20 Insertions

On July 2, 2025, the FDA granted accelerated approval to Sunvozertinib (brand name: Zegfrovy) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations who have progressed on or after platinum-based chemotherapy.

Drug Summary

  • Name: Sunvozertinib (Zegfrovy)
  • Company: Dizal (Jiangsu) Pharmaceutical Co., Ltd.
  • Indication: EGFR exon 20 insertion mutation–positive advanced or metastatic NSCLC (post-platinum)
  • Mechanism: EGFR-targeted tyrosine kinase inhibitor (TKI)
  • Dose: 200 mg orally, once daily with food

Clinical Trial: WU-KONG1B (NCT03974022)

A global, open-label Phase 1/2 study. Primary endpoint was confirmed objective response rate (ORR) per RECIST v1.1 by independent review.

  • ORR: 46% (95% CI: 35–57)
  • Duration of Response: Median 11.1 months (95% CI: 8.2, NE)

Safety Profile

Warnings and precautions in the label include:

  • Interstitial lung disease (ILD)/pneumonitis
  • GI, dermatologic, and ocular toxicities
  • Embryo-fetal toxicity

Companion Diagnostic

On the same day, the FDA also approved the Oncomine Dx Express Test to detect EGFR exon 20 insertions for treatment eligibility.

Significance

This is the first accelerated approval of an oral TKI specifically for EGFR exon 20 insertion–positive NSCLC—a critical development for patients with limited targeted therapy options.

References

Comment Guideline

💬 Before leaving a comment, please review our [Comment Guidelines].

Let's share this post !

Author of this article

After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.

Comments

To comment

CAPTCHA


TOC